ALT | (elevated) |
---|---|
anti-HAV IgM | + |
anti-HAV IgG** | - |
anti-HAV total** | + |
HAV RNA | + |
Symptoms | - |
* Detection of serum IgM antibodies in the absence of clinical symptoms may reflect prior hepatitis A infection with prolonged persistence of IgM, a false positive result, or asymptomatic infection (which is more common in children <6 years of age than older children or adults). People who test positive for anti-HAV IgM more than 1 year after infection have been reported.
** These markers will also be detected after receiving the HAV vaccine, so they may be used to determine whether a person has developed immunity after vaccination. (…) = potentially present
ALT | elevated |
---|---|
anti-HAV IgM | + |
anti-HAV IgG** | (+) |
anti-HAV total** | + |
HAV RNA | (+) |
Symptoms | + |
* Detection of serum IgM antibodies in the absence of clinical symptoms may reflect prior hepatitis A infection with prolonged persistence of IgM, a false positive result, or asymptomatic infection (which is more common in children <6 years of age than older children or adults). People who test positive for anti-HAV IgM more than 1 year after infection have been reported.
** These markers will also be detected after receiving the HAV vaccine, so they may be used to determine whether a person has developed immunity after vaccination. (…) = potentially present
ALT | normal |
---|---|
anti-HAV IgM | (+)* |
anti-HAV IgG** | + |
anti-HAV total** | + |
HAV RNA | - |
Symptoms | - |
* Detection of serum IgM antibodies in the absence of clinical symptoms may reflect prior hepatitis A infection with prolonged persistence of IgM, a false positive result, or asymptomatic infection (which is more common in children <6 years of age than older children or adults). People who test positive for anti-HAV IgM more than 1 year after infection have been reported.
** These markers will also be detected after receiving the HAV vaccine, so they may be used to determine whether a person has developed immunity after vaccination. (…) = potentially present
Adapted from:
a) for use on the cobas® e 411 analyzer and the cobas® e 601 / 602 modules;
b) for use on the cobas® e 402 and cobas® e 801 analytical units
c) in-process test of plasma intended for further manufacture collected from donors of whole blood, blood components, or plasma; not intended for use as an aid in diagnosis for HAV; for use on the cobas® 6800/8800
Systems
anti-HAV IgM | anti-HAV total | Results indicate |
---|---|---|
positive | not performed or positive | Acute or recent HAV infection |
negative* | positive | No active infection but previous HAV exposure; has developed immunity to HAV or was recently vaccinated for HAV; no further testing required |
not performed | positive | Has been exposed to HAV, but does not rule out acute infection |
not performed or negative | negative | No current or previous HAV infection; vaccination may be recommended if at risk |
* Approximately 3 % of HAV-infected people will be IgM negative if blood is drawn on or before the day of onset of jaundice. Suspicious cases with negative IgM results from such early samples should be retested in 4 – 7 days to rule out the diagnosis.7
Adapted from:
Acute or recent HAV infection
Consider supportive care and controlling signs and symptoms.
No specific treatment exists for acute hepatitis A infection.
No current or previous HAV
Vaccination may be recommended for person at increased risk for HAV infection.
No active infection but previous HAV exposure or vaccination
No further testing required
Perform anti-HAV total antibodies test
Approx. 3% of HAV-infected people will be IgM negative if sample is taken on or before the day of onset of jaundice. Suspicious cases with negative IgM results from such early samples should be retested after 4-7 days.